Figure 3

Overall survival curves according to patient group. A, among 1,048 patients, HER2-positive breast carcinoma tended to display the worst 5-year overall survival by log-rank analysis; our ER-positive and/or PgR-positive and HER2-negative patients had the best 5-year DFS; p < 0.0001. B, in the node-positive patients, TNBC tended to demonstrate the worst 5-year overall survival by log-rank analysis; ER-positive and/or PgR-positive and HER2-negative patients had the best 5-year overall survival; p < 0.0001. C, in the node-negative patients, four subgroups showed no 5-year overall survival difference, by log-rank analysis; p = 0.8620. We followed up the node-negative HER2-positive patients up to 48 months.